The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Sirius JV will be owned 51% by Sirius and 49% by Adani
Marks remarkable acceleration in innovation using AI technology
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Expands patient reach to remotest towns by furthering investment in GoApptiv
Subscribe To Our Newsletter & Stay Updated
